Paclitaxel (Taxol): An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer

Derick H Lau, Ling Xue, Lawrence J. Young, Patricia A. Burke, Anthony T. Cheung

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Paclitaxel (Taxol), a promoter of microtubule polymerization and a radiosensitizing agent, is one of the more active anticancer drugs in the current treatment of solid tumors. In this study, we show that paclitaxel possesses an antiangiogenic property associated with a down-regulation of vascular endothelial growth factor (VEGF) in a highly-vascularized transgenic murine breast cancer (Met-1). Paclitaxel, at non-cytotoxic doses of 0, 3 and 6 mg/kg/day, was administered intraperitoneally for 5 days to nude mice bearing the Met-1 breast tumor. Extent of intratumoral angiogenesis, as indicated by microvessel tortuosity and microvessel density, was significantly reduced by paclitaxel in a dose-dependent manner. Paclitaxel also suppressed expression of VEGF in the Met-1 cells transplanted in nude mice or maintained in cell culture. These results indicate that antiangiogenesis associated with a down-regulation of VEGF is an additional mode of action of paclitaxel.

Original languageEnglish (US)
Pages (from-to)31-36
Number of pages6
JournalCancer Biotherapy and Radiopharmaceuticals
Volume14
Issue number1
StatePublished - 1999

Fingerprint

Angiogenesis Inhibitors
Paclitaxel
Breast Neoplasms
Vascular Endothelial Growth Factor A
Microvessels
Nude Mice
Down-Regulation
Radiation-Sensitizing Agents
Microtubules
Polymerization
Cell Culture Techniques
Pharmaceutical Preparations

Keywords

  • Anti-angiogenesis
  • Breast cancer
  • Paclitaxel
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Paclitaxel (Taxol) : An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. / Lau, Derick H; Xue, Ling; Young, Lawrence J.; Burke, Patricia A.; Cheung, Anthony T.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 14, No. 1, 1999, p. 31-36.

Research output: Contribution to journalArticle

Lau, Derick H ; Xue, Ling ; Young, Lawrence J. ; Burke, Patricia A. ; Cheung, Anthony T. / Paclitaxel (Taxol) : An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. In: Cancer Biotherapy and Radiopharmaceuticals. 1999 ; Vol. 14, No. 1. pp. 31-36.
@article{1311ef227ff64c6ebefc3a2c78bf5314,
title = "Paclitaxel (Taxol): An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer",
abstract = "Paclitaxel (Taxol), a promoter of microtubule polymerization and a radiosensitizing agent, is one of the more active anticancer drugs in the current treatment of solid tumors. In this study, we show that paclitaxel possesses an antiangiogenic property associated with a down-regulation of vascular endothelial growth factor (VEGF) in a highly-vascularized transgenic murine breast cancer (Met-1). Paclitaxel, at non-cytotoxic doses of 0, 3 and 6 mg/kg/day, was administered intraperitoneally for 5 days to nude mice bearing the Met-1 breast tumor. Extent of intratumoral angiogenesis, as indicated by microvessel tortuosity and microvessel density, was significantly reduced by paclitaxel in a dose-dependent manner. Paclitaxel also suppressed expression of VEGF in the Met-1 cells transplanted in nude mice or maintained in cell culture. These results indicate that antiangiogenesis associated with a down-regulation of VEGF is an additional mode of action of paclitaxel.",
keywords = "Anti-angiogenesis, Breast cancer, Paclitaxel, VEGF",
author = "Lau, {Derick H} and Ling Xue and Young, {Lawrence J.} and Burke, {Patricia A.} and Cheung, {Anthony T.}",
year = "1999",
language = "English (US)",
volume = "14",
pages = "31--36",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Paclitaxel (Taxol)

T2 - An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer

AU - Lau, Derick H

AU - Xue, Ling

AU - Young, Lawrence J.

AU - Burke, Patricia A.

AU - Cheung, Anthony T.

PY - 1999

Y1 - 1999

N2 - Paclitaxel (Taxol), a promoter of microtubule polymerization and a radiosensitizing agent, is one of the more active anticancer drugs in the current treatment of solid tumors. In this study, we show that paclitaxel possesses an antiangiogenic property associated with a down-regulation of vascular endothelial growth factor (VEGF) in a highly-vascularized transgenic murine breast cancer (Met-1). Paclitaxel, at non-cytotoxic doses of 0, 3 and 6 mg/kg/day, was administered intraperitoneally for 5 days to nude mice bearing the Met-1 breast tumor. Extent of intratumoral angiogenesis, as indicated by microvessel tortuosity and microvessel density, was significantly reduced by paclitaxel in a dose-dependent manner. Paclitaxel also suppressed expression of VEGF in the Met-1 cells transplanted in nude mice or maintained in cell culture. These results indicate that antiangiogenesis associated with a down-regulation of VEGF is an additional mode of action of paclitaxel.

AB - Paclitaxel (Taxol), a promoter of microtubule polymerization and a radiosensitizing agent, is one of the more active anticancer drugs in the current treatment of solid tumors. In this study, we show that paclitaxel possesses an antiangiogenic property associated with a down-regulation of vascular endothelial growth factor (VEGF) in a highly-vascularized transgenic murine breast cancer (Met-1). Paclitaxel, at non-cytotoxic doses of 0, 3 and 6 mg/kg/day, was administered intraperitoneally for 5 days to nude mice bearing the Met-1 breast tumor. Extent of intratumoral angiogenesis, as indicated by microvessel tortuosity and microvessel density, was significantly reduced by paclitaxel in a dose-dependent manner. Paclitaxel also suppressed expression of VEGF in the Met-1 cells transplanted in nude mice or maintained in cell culture. These results indicate that antiangiogenesis associated with a down-regulation of VEGF is an additional mode of action of paclitaxel.

KW - Anti-angiogenesis

KW - Breast cancer

KW - Paclitaxel

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=0032930199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032930199&partnerID=8YFLogxK

M3 - Article

C2 - 10850285

AN - SCOPUS:0032930199

VL - 14

SP - 31

EP - 36

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 1

ER -